Erratum: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma (International Journal of Oncology (2014) 44 (1843-1852) DOI: 10.3892/ijo.2014.2382);ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 1843-1852

  Rieger, Johannes ^a,f   Bähr, Oliver ^a   Maurer, Gabriele D ^a   Hattingen, Elke ^b   Franz, Kea ^b   Brucker, Daniel ^a   Walenta, Stefan ^c   Kämmerer, Ulrike ^d   Coy, Johannes F ^e   Weller, Michael ^f,g   Steinbach, Joachim P ^a,f  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Darmstadt and Tavargenix GmbH   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Feasibility; Glioma; Glucose; Ketogenic diet; Metabolism

Indexed keywords

BEVACIZUMAB; CARBOHYDRATE; CARMUSTINE; LOMUSTINE; NIMUSTINE; NITROSOUREA; TEMOZOLOMIDE; TENIPOSIDE; VEGETABLE OIL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; YOGHURT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; KETOACIDOSIS; KETOGENIC DIET; LEUKOPENIA; LOW CARBOHYDRATE DIET; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THERAPY EFFECT; URINE; CANCER THERAPY; FOLLOW UP; MOUSE; NUCLEAR MAGNETIC RESONANCE SCANNER; RANDOMIZATION; RECURRENT GLIOBLASTOMA; TREATMENT DURATION; URINALYSIS; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL; DIET THERAPY; EXPERIMENTAL NEOPLASM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; QUALITY OF LIFE; SURVIVAL ANALYSIS; THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; KETOGENIC DIET; KETOSIS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; PILOT PROJECTS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84899566522     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2681     Document Type: Erratum

References (53)

1. Warburg O, Posener K and Negelein E: Ueber den Stoffwechsel der Tumoren. Biochem Z 152: 319-344, 1924 (in German).
2. TCGA: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
3. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004.
4. Matoba S, Kang J, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F and Hwang PM: p53 regulates mitochondrial respiration. Science 312: 1650-1653, 2006.
5. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP and Rieger J: Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene 31: 3764-3776, 2012.
6. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E and Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
7. Wanka C, Steinbach JP and Rieger J: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem 287: 33436-33446, 2012.
8. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713, 2008.
9. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC: HIF-1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 3: 187-197, 2006.
10. Liu Y, Li Y, Tian R, Liu W, Fei Z, Long Q, Wang X and Zhang X: The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res 1304: 149-154, 2009.
11. Roslin M, Henriksson R, Bergström P, Ungerstedt U and Bergenheim AT: Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61: 151-160, 2003.
12. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G and Mantil JC: Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64: 227-237, 2003.
13. Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, Yamaguchi S, Houkin K, Tanaka S, Kuge Y and Tamaki N: (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 39: 760-770, 2012.
14. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, Jindal A, Jeffrey FM, Choi C, Madden C, Mathews D, Pascual JM, Mickey BE, Malloy CR and Deberardinis RJ: Metabolism of [U-(13) C]glucose in human brain tumors in vivo. NMR Biomed 25: 1234-1244, 2012.
15. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang X, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Matés JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ and Bachoo RM: Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15: 827-837, 2012.
16. Ward PS and Thompson CB: Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308, 2012.
17. Jeon S, Chandel NS and Hay N: AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-665, 2012.
18. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B and Hood N: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 42-51, 2002.
19. Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO and Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915, 1998.
20. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR, Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez M, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E and Kaaks R: Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16: 1121-1127, 2007.
21. Renehan AG, Egger M, Minder C, O'Dwyer ST, Shalet SM and Zwahlen M: IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer 115: 1006-1007; author reply, 1008, 2005.
22. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 29: 1990-1991, 2006.
23. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD and Grossman SA: Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27: 1082-1086, 2009.
24. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG and Seyfried TN: The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4: 5, 2007.
25. Marsh J, Mukherjee P and Seyfried TN: Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 14: 7751-7762, 2008.
26. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM and Scheck AC: The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7: 74, 2010.
27. Kossoff EH, Rowley H, Sinha SR and Vining EPG: A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 49: 316-319, 2008.
28. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M and Stampfer MJ: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 359: 229-241, 2008.
29. Fraser DA, Thoen J, Bondhus S, Haugen M, Reseland JE, Djøseland O, Førre O and Kjeldsen-Kragh J: Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients. Clin Exp Rheumatol 18: 209-214, 2000.
30. Accurso A, Bernstein RK, Dahlqvist A, Draznin B, Feinman RD, Fine EJ, Gleed A, Jacobs DB, Larson G, Lustig RH, Manninen AH, McFarlane SI, Morrison K, Nielsen JV, Ravnskov U, Roth KS, Silvestre R, Sowers JR, Sundberg R, Volek JS, Westman EC, Wood RJ, Wortman J and Vernon MC: Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) 5: 9, 2008.
31. Nebeling LC, Miraldi F, Shurin SB and Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14: 202-208, 1995.
32. Schmidt M, Pfetzer N, Schwab M, Strauss I and Kämmerer U: Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 8: 54, 2011.
33. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, Bontempo AF, Negassa A and Sparano JA: Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 28: 1028-1035, 2012.
34. Macdonald DR, Cascino TL, Schold SCJ and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
35. Mueller-Klieser W and Walenta S: Geographical mapping of metabolites in biological tissue with quantitative biolumines cence and single photon imaging. Histochem J 25: 407-420, 1993.
36. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP and Rieger J: Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 11: 315, 2011.
37. Chang HT, Olson LK and Schwartz KA: Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab (Lond) 10: 47, 2013.
38. Steinbach JP, Wolburg H, Klumpp A, Probst H and Weller M: Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 10: 823-832, 2003.
39. Rieger J, Bähr O, Müller K, Franz K, Steinbach J and Hattingen E: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99: 49-56, 2010.
40. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y and Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12: 233-242, 2010.
41. DeLay M, Jahangiri A, Carbonell WS, Hu Y, Tsao S, Tom MW, Paquette J, Tokuyasu TA and Aghi MK: Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18: 2930-2942, 2012.
42. Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP and Pilatus U: Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol 13: 1349-1363, 2011.
43. Tamura H, Hatazawa J, Toyoshima H, Shimosegawa E and Okudera T: Detection of deoxygenation-related signal change in acute ischemic stroke patients by T2*-weighted magnetic resonance imaging. Stroke 33: 967-971, 2002.
44. Seiler A, Jurcoane A, Magerkurth J, Wagner M, Hattingen E, Deichmann R, Neumann-Haefelin T and Singer OC: T2′ imaging within perfusion-restricted tissue in high-grade occlusive carotid disease. Stroke 43: 1831-1836, 2012.
45. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, Voelker HU, Thiede A and Coy JF: Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 8: 122, 2008.
46. Liu AG, Most MM, Brashear MM, Johnson WD, Cefalu WT and Greenway FL: Reducing the glycemic index or carbohydrate content of mixed meals reduces postprandial glycemia and insulinemia over the entire day but does not affect satiety. Diabetes Care 35: 1633-1637, 2012.
47. Mukherjee P, Mulrooney TJ, Marsh J, Blair D, Chiles TC and Seyfried TN: Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Mol Cancer 7: 37, 2008.
48. Sarkar NH, Fernandes G, Telang NT, Kourides IA and Good RA: Low-calorie diet prevents the development of mammary tumors in C3H mice and reduces circulating prolactin level, murine mammary tumor virus expression, and proliferation of mammary alveolar cells. Proc Natl Acad Sci USA 79: 7758-7762, 1982.
49. Giovanella BC, Shepard RC, Stehlin JS, Venditti JM and Abbott BJ: Calorie restriction: effect on growth of human tumors heterotransplanted in nude mice. J Natl Cancer Inst 68: 249-257, 1982.
50. Kalaany NY and Sabatini DM: Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731, 2009.
51. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R and Longo VD: Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4: 124ra27, 2012.
52. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P and Scheck AC: The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE 7: e36197, 2012.
53. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P and Seyfried TN: Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab (Lond) 7: 33, 2010.